KALA BIO (NASDAQ:KALA - Get Free Report) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating in a research report issued on Wednesday,Zacks.com reports. Lifesci Capital also issued estimates for KALA BIO's Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.11) EPS, FY2025 earnings at ($4.94) EPS, Q1 2026 earnings at ($1.14) EPS, Q2 2026 earnings at ($1.17) EPS, Q3 2026 earnings at ($1.26) EPS, Q4 2026 earnings at ($1.29) EPS and FY2026 earnings at ($4.87) EPS.
Other analysts also recently issued research reports about the stock. LADENBURG THALM/SH SH began coverage on shares of KALA BIO in a research report on Friday, July 11th. They issued a "buy" rating and a $12.00 price target for the company. HC Wainwright cut their price objective on shares of KALA BIO from $15.00 to $12.00 and set a "buy" rating for the company in a research report on Friday, May 23rd. Oppenheimer restated an "outperform" rating and set a $15.00 price objective on shares of KALA BIO in a research report on Monday, June 2nd. Finally, Wall Street Zen downgraded shares of KALA BIO from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $17.25.
Check Out Our Latest Analysis on KALA
KALA BIO Stock Performance
KALA stock traded down $0.97 on Wednesday, hitting $13.51. The company's stock had a trading volume of 120,263 shares, compared to its average volume of 102,561. The firm has a 50 day moving average of $7.98 and a two-hundred day moving average of $5.85. KALA BIO has a 1 year low of $2.92 and a 1 year high of $15.80. The stock has a market cap of $94.82 million, a price-to-earnings ratio of -1.99 and a beta of -1.82. The company has a current ratio of 2.10, a quick ratio of 2.10 and a debt-to-equity ratio of 3.19.
KALA BIO (NASDAQ:KALA - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported ($1.71) EPS for the quarter, beating the consensus estimate of ($1.82) by $0.11. Equities analysts predict that KALA BIO will post -10.84 EPS for the current fiscal year.
Insider Buying and Selling
In related news, Director Mark T. Iwicki sold 13,227 shares of the stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $4.01, for a total value of $53,040.27. Following the sale, the director directly owned 258,433 shares of the company's stock, valued at approximately $1,036,316.33. This represents a 4.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders have sold 30,678 shares of company stock valued at $123,019. 8.32% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On KALA BIO
A number of large investors have recently added to or reduced their stakes in the business. AIGH Capital Management LLC grew its stake in KALA BIO by 52.8% in the 2nd quarter. AIGH Capital Management LLC now owns 300,000 shares of the company's stock valued at $1,428,000 after acquiring an additional 103,650 shares during the last quarter. ADAR1 Capital Management LLC grew its stake in KALA BIO by 35.7% in the 1st quarter. ADAR1 Capital Management LLC now owns 298,955 shares of the company's stock valued at $1,713,000 after acquiring an additional 78,582 shares during the last quarter. Woodline Partners LP acquired a new stake in KALA BIO in the 1st quarter valued at about $1,483,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in KALA BIO by 10.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 178,934 shares of the company's stock valued at $1,242,000 after acquiring an additional 16,271 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in KALA BIO by 2.8% in the 2nd quarter. Geode Capital Management LLC now owns 56,367 shares of the company's stock valued at $268,000 after acquiring an additional 1,534 shares during the last quarter. 24.61% of the stock is owned by institutional investors and hedge funds.
KALA BIO Company Profile
(
Get Free Report)
KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.
Further Reading
Before you consider KALA BIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KALA BIO wasn't on the list.
While KALA BIO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
